The Queen Elizabeth Hospital
Welcome,         Profile    Billing    Logout  
 22 Trials 
63 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Townsend, Amanda
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Price, Tim
NCT05159388: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Active, not recruiting
1/2
45
Europe, US, RoW
PRS-344/S095012
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Solid Tumor
07/25
07/25
NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
McIntyre, Kristi J
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark Elderly chemo-intolerant Hodgkin's lymphoma patients
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
PATHFINDER 2, NCT05155605: a Multi-Cancer Early Detection Study

Active, not recruiting
N/A
35885
Canada, US
Multi-Cancer Early Detection Test
GRAIL, Inc.
Early Detection of Cancer, Cancer
02/26
04/28
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Wachter, Eric
PV-10-MM-1201, NCT02557321: PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Active, not recruiting
1/2
50
US
PV-10, Rose Bengal Disodium, Pembrolizumab
Provectus Biopharmaceuticals, Inc.
Melanoma
05/23
04/25
PV-10-NET-01, NCT02693067: A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Active, not recruiting
1
12
RoW
Rose bengal disodium, PV-10
Provectus Biopharmaceuticals, Inc.
Neuroendocrine Tumors Metastatic to the Liver
09/21
09/23
PV-10-LC-01, NCT00986661: A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Active, not recruiting
1
78
US
PV-10 (10% rose bengal disodium)
Provectus Biopharmaceuticals, Inc.
Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer
12/22
02/23
Price, Timothy
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
nextHERIZON, NCT05311176: A Study of IMU-131 (HER-Vaxx) in Combination with Chemotherapy or Pembrolizumab in Patients with Metastatic HER2/neu Over-Expressing Gastric Cancer

Completed
2
7
RoW
IMU-131, HER-Vaxx, Ramucirumab plus Paclitaxel, Standard of Care Chemotherapy, Pembrolizumab, Keytruda
Imugene Limited
Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer, Stomach Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
04/24
04/24
ASCEND, NCT05042128: The Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
158
RoW
LSTA1, CEND-1, certepetide, Gemcitabine Injection, Gemzar, Nab paclitaxel, Abraxane
Australasian Gastro-Intestinal Trials Group, University of Sydney
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
06/25
10/25
BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting
2
80
Europe, US
LSTA1, certepetide, CEND-1, Durvalumab, Imfinzi, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo
Lisata Therapeutics, Inc.
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
03/26
03/26
NCT05427487: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Recruiting
1
70
RoW
IVX037, Sintilimab
ImmVirx Pty Ltd, Innovent Biologics (Suzhou) Co. Ltd.
Colorectal Cancer, Gastric Cancer, Ovarian Cancer
09/26
11/26
Bryant, Robert
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting
4
304
Europe, Canada, US, RoW
Vedolizumab
Alimentiv Inc., Takeda
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
01/27
09/28
Reid, Jessica
ACTRN12620001228976: Proof of concept: can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O) be added to standard treatment for resectable high-risk gastric cancer patients?

Not yet recruiting
1
10
 
The Queen Elizabeth Hospital , The Queen Elizabeth Hospital
Gastric cancer
 
 
NCT03907735: Oxytocin Receptor Expression in Pregnancy

Active, not recruiting
N/A
30
US
Myometrial tissue sample collection
Oregon Health and Science University
Post-Abortion, Hemorrhage, Obstetric
08/20
12/24
NCT05339555: IUD Self-Removal Study

Recruiting
N/A
30
US
Instructions for IUD Self-Removal Provided to Participant
Oregon Health and Science University
IUD
12/24
12/24
Hammerl, Peter
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
150
Europe, Canada, US, RoW
GSK3915393, Placebo
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
03/26
03/26
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
270
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
02/27
03/27
NCT06154837: A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

Recruiting
1
130
Europe
GSK3862995B, Placebo
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
04/26
04/26
NCT03318406: Post-Market BTVA Registry

Recruiting
N/A
300
Europe
Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor
Uptake Medical Technology, Inc.
Emphysema or COPD
12/27
12/30
NCT05717192: BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation

Recruiting
N/A
224
Europe
InterVapor®-System
IHF GmbH - Institut für Herzinfarktforschung
Emphysema or Chronic Obstructive Pulmonary Disease
04/26
12/27
Thomas, Vibha
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Vidal, Gregory
OnTARGET, NCT04538625: Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Completed
3
287
US, RoW
Crofelemer 125 MG [Mytesi], Placebo
Napo Pharmaceuticals, Inc.
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
08/23
10/23
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
FACT-2, NCT03812393: Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

Hourglass Oct 2021 - Mar 2022 : Interim data from FACT-2 trial for early stage TNBC-negative that respond to pan-HER drugs
Active, not recruiting
2
27
US
Neratinib, Live Cell HER2 signaling Transduction Analysis (CELx)
West Cancer Center, Celcuity Inc, Puma Biotechnology, Inc.
Triple Negative Breast Cancer, Early-stage Breast Cancer, HER2-positive Breast Cancer
12/24
12/24
DIDO, NCT04983745: Niraparib and Dostarlimab in HRD Solid Tumors

Recruiting
2
30
US
Combination drug
West Cancer Center
Homologous Recombination Deficient Solid Tumors
08/24
08/25
Short, Cathy
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Roberts-Thomson, Rachel
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
STOP-GAP, NCT02821013: Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
3
614
Canada, RoW
Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
Canadian Cancer Trials Group, Melanoma and Skin Cancer Trials Limited
Unresectable/Metastatic Melanoma
12/27
12/29
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Terminated
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
12/23
12/23
Psaltis, Peter
ASPIRE-AF, NCT03968393 / 2019-001336-62: Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

Recruiting
4
2270
Europe, Canada, RoW
Non-vitamin K oral anticoagulant (NOAC), Apixaban, Dabigatran, Edoxaban, Rivaroxaban
Population Health Research Institute, Hamilton Health Sciences Corporation
Stroke, Atrial Fibrillation
12/26
12/28
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
ACTRN12618000809235: COCOMO-ACS Study: The Colchicine for coronary plaque modification in Acute Coronary Syndrome Study

Completed
2
64
 
South Australian Health and Medical Research Insititute, NHMRC, Heart Foundation
Acute Coronary Syndrome, Coronary Artery Disease, Non-ST elevation myocardial infarction
 
 
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Completed
2
233
Europe, Japan, US, RoW
LY3473329, Placebo
Eli Lilly and Company
Lipoprotein Disorder
03/24
03/24
Pham, Chi M
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Matson, Wendy C
NCT05945537: A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Recruiting
1
96
RoW
INI-822 (A), Placebo (B)
Inipharm Australia Pty Ltd
Non-alcoholic Steatohepatitis
11/24
12/24
Investigator, Simon Perkins Principal
ROADMAP, NCT06771050: Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform () Trial is an International RCT Evaluating the Effect of a Range of Clinical Surgical and Antibiotic Interventions on Treatment Success 12 Mths Post-platform Entry in Adults With Prosthetic Joint Infection (PJI)

Not yet recruiting
4
2500
RoW
Debridement and Implant Retention (DAIR), Revision Arthroplasty - Single stage revision, Antibiotic Choice, No intervention: Standard of Care "Backbone antibiotics", Intervention: Standard of care " Backbone antibiotics" + Rifampicin antibiotics, Antibiotic duration Part A - Single stage revision, shorter duration - 6 weeks, longer duration - 12 weeks, Antibiotic Duration Part B - Two stage revision, Extended antibiotic prophylaxis following 2nd stage Revision operation, No extended antibiotic prophylaxis following 2nd stage Revision operation
University of Newcastle, Australia, Hunter Medical Research Institute (HMRI), The University of Western Australia, Michael Garron Hospital, Aotearoa Clinical Trials, Exeter Orthopaedic Trial unit, University of Sydney, University of Melbourne, The Peter Doherty Institute for Infection and Immunity
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Large Joint Prosthetic Joint Infections
02/28
12/29

Download Options